We investigated whether matrix metalloproteinase-8 (MMP8) played a role in SPC migration and their recruitment into atheromas. MMP8 cleaved a-disintegrin-and-metalloproteinase-domain-10  and that MMP8 deficiency reduced mature a-disintegrin-and-metalloproteinase-domain-10 on SPCs. Knockdown of MMP8 or incubation with the a-disintegrin-and-metalloproteinase-domain-10 inhibitor GI254023X decreased E-cadherin shedding on SPCs. The decrease in migratory ability of SPCs with MMP8 knockdown was reduced by incubation of such cells with culture supernatant from SPCs without MMP8 knockdown, and this compensatory effect was abolished by an antibody against soluble E-cadherin. Conclusions: MMP8 plays an important role in SPC migration and their recruitment into atherosclerotic lesions. (Circ Res. 2013;112:35-47.)
T he pathogenesis of atherosclerosis is a chronic inflammatory process initiated by biochemical and mechanical insults such as elevated level of low-density lipoprotein cholesterol and high blood pressure. 1 Major constituents of atherosclerotic lesions include lipids, macrophages, smooth muscle cells (SMCs), and extracellular proteins, especially collagen I and III. Traditionally, it is thought that the accumulation of SMCs in atheromas results from migration of resident SMCs from the arterial media into the intima, where SMCs undergo proliferation, and that the accumulation of monocytes/macrophages is the result of infiltration of circulating monocytes into the intima, where they differentiate into macrophages. Recent evidence, however, indicates that stem/progenitor cells (SPCs) represent another source of SMCs 2-5 and monocytes/macrophages [6] [7] [8] [9] [10] in atheromas and contribute to atherosclerotic lesion formation and progression. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Studies have identified 2 sources for SPCs in atherosclerotic lesions: (1) bone marrow-derived SPCs that are recruited into atherosclerotic lesions via the blood circulation and (2) local SPCs in the vascular wall that can migrate into atherosclerotic lesions. 3, 10 However, the mechanisms by which SPCs are mobilized from their original sites and recruited into the atheroma are currently incompletely elucidated.
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases with proteolytic activity on a variety of proteins. Collectively, the MMPs can degrade all proteins that constitute the interstitial extracellular matrix and the basement membrane. Moreover, a growing number of nonmatrix proteins have been shown to be susceptible to cleavage by MMPs. In some cases, such cleavage leads to increased activity of the proteins concerned, whereas in some other cases, the cleavage results in diminished activity. 14 There is evidence indicating that certain MMPs play important roles in SPC mobilization, homing, and migration into destination tissues. For example, studies have shown that MMP9, whose expression is induced by nitric oxide, 15 can cleave the membrane-bound kit ligand (also known as stem cell factor), leading to the release of this cytokine, which promotes transfer of SPCs from quiescent to proliferative niches in the bone marrow. 16 It also has been demonstrated that MMP9 facilitates the incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization. 17 Another MMP, namely MMP14, has been shown to play a role in granulocyte colony-stimulating factor-induced progenitor cell mobilization, such that MMP14, activated by this cytokine, cleaves off the protein CD44 on progenitor cells and thus disrupts CD44-mediated binding of progenitor cells to the basement membrane in the bone marrow, thereby promoting progenitor cell mobilization and egress. 18 Taken together, these studies indicate that different MMPs play divergent roles in SPC mobilization or migration.
MMP8 (also known as collagenase-2) has potent proteolytic activity on fibrillar collagens, particularly collagen I. 19 It also can degrade other matrix proteins such as laminin and fibronectin. 19 In addition, it has been shown to be able to cleave the chemokines CXCL5 20 and CXCL11. 21 Studies of polymorphonuclear cells have shown that a substantial proportion of MMP8 binds to the cell plasma membrane and that the membrane-bound MMP8 contributes importantly to collagen I degradation. 22 Previous studies by other researchers have shown that macrophages, SMCs, and endothelial cells in atherosclerotic lesions express MMP8, 23 that lesion progression is associated with increased MMP8 expression, 24 and that increased plasma MMP8 levels correlate with increased risk of cardiovascular mortality, 25 indicating a connection between MMP8 and atherosclerosis. Further to those studies, we recently showed that MMP8 deficiency reduced atherosclerotic lesion formation in apolipoprotein E (ApoE) knockout mice fed a Western diet, with reduced lesional macrophage and SMC content, 26 suggesting a causal role of MMP8 in the pathogenesis of atherosclerosis. Because of the complexity of atherogenesis and potentially a wide range of proteins that might be susceptible to cleavage by MMP8, it is possible that multiple different mechanisms contribute to the role of MMP8 in atherosclerotic lesion formation and progression, and further work would be required to elucidate the mechanisms involved. In this study, we found evidence of an important role of MMP8 in SPC migration and their recruitment into atherosclerotic lesions.
Methods
Detailed Methods are provided in the Online Data Supplement. In brief, microscopic sections of aortic root atherosclerotic lesions from ApoE −/− /MMP8 −/− and ApoE −/− /MMP8 +/+ mice fed 26 a Western diet for 12 weeks were subjected to hematoxylin and eosin staining and immunostaining for MMP8, Sca-1, CD34, c-kit, and Flk-1, respectively. In stem cell injection experiments, SPCs were isolated from bone marrows of ApoE −/− /MMP8 −/− and ApoE −/− /MMP8 +/+ mice, respectively, and injected into ApoE −/− /MMP8 −/− mice via the tail vein (1×10 6 SPCs/mice). The mice were then fed a Western diet for 6 weeks or 12 weeks, and microscopic sections of aortic root atherosclerotic lesions were subjected to hematoxylin and eosin staining and immunostaining for Sca-1, c-kit, CD45, CD68, smooth muscle actin, and smooth muscle myosin heavy chain, respectively. In ex vivo transendothelial migration experiments, fluorescence-labeled embryonic Sca-1 + SPCs that had been infected with MMP8 shRNA to knockdown MMP8 or nontarget shRNA to serve as controls were injected into the lumen of explants of aortas with atherosclerotic lesions; after closure of both ends of the vessels by ligation, the explants were cultured in the presence of stromal cell-derived factor-1α for 24 hours, followed by examination of fluorescence-labeled cells in the atherosclerotic lesions. In ex vivo transadventitia migration experiments, fluorescence-labeled embryonic Sca-1 + SPCs that had been infected with MMP8 shRNA or nontarget shRNA were embedded in Matrigel and then patched around the adventitia of explants of atherosclerotic aortas connected to a microcirculation system with circulating progenitor cell culture medium supplemented with stromal cell-derived factor-1α; after 24 hours of incubation, fluorescence-labeled cells in the atherosclerotic lesions were examined.
Embryonic Sca-1 + SPCs with or without exogenous MMP8 coating, embryonic Sca-1 + SPCs that had been infected with MMP8 shRNA or nontarget shRNA (the efficiency and specificity of MMP8 shRNA knockdown in embryonic Sca-1 + SPCs are shown in Online Figure I ), and bone marrow-derived Sca-1 + SPCs from MMP8 −/− or MMP8 +/+ mice were subjected to assays for migration across an endothelial monolayer or through a variety of different types of matrix proteins as follows: Matrigel, collagen I, collagen IV, gelatin, fibronectin, and elastin, respectively.
Western blot analyses and flow cytometry assays were performed to examine pro-a-disintegrin-and-metalloproteinase-domain-10 (ADAM10) and mature ADAM10 on embryonic Sca-1 + SPCs infected with MMP8 shRNA or nontarget shRNA. A recombinant ADAM10 (amino acids 19-673) consisting of the prodomain and the other ectodomains were incubated with or without active MMP8 and subjected to Western blot analysis. Western blot analyses and flow cytometry assays were performed to examine full-length E-cadherin and shed E-cadherin on embryonic Sca-1 + SPCs that had been infected with MMP8 shRNA or nontarget shRNA and had been incubated with or without the ADAM10 inhibitor GI254023X. 27, 28 Embryonic Sca-1 + SPCs with MMP8 knockdown were cultured in the presence or absence of culture supernatant from embryonic Sca-1 + SPCs without MMP8 knockdown, and in the presence or absence of an antibody against soluble E-cadherin, and then were subjected to assays for migration through collagen I. Levels of soluble E-cadherin in plasma samples from ApoE −/− /MMP8 +/+ and ApoE −/− /MMP8 −/− mice were measured with the use of a commercially available ELISA kit. 
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Results
SPCs in Culture and Atherosclerotic Lesions Express MMP8
Previously, in an RNA microarray analysis of Sca-1 + SPCs derived from embryonic stem cells, 29, 30 we noted that they expressed MMP8 mRNA (unpublished data). In this study, we performed Western blot analysis and detected substantial levels of MMP8 protein in cultured Sca-1 + SPCs derived from embryonic stem cells, bone marrow Sca-1 + SPCs, leukocytes, SMCs, and endothelial cells ( Figure 1A ). Immunocytochemical analysis further confirmed the expression of MMP8 in cultured Sca-1 + SPCs ( Figure 1B ). We found that MMP8 expression in embryonic Sca-1 + SPCs was increased after incubation with 4-hydroxynonenal and 7-ketocholesterol, components of oxidized low-density lipoprotein cholesterol ( Figure 1C ). Furthermore, immunohistochemical examination in atherosclerotic lesions from ApoE-deficient (ApoE −/− / MMP8 +/+ ) mice fed a Western diet for 12 weeks showed that Sca-1 + SPCs in atherosclerotic lesions expressed MMP8 ( Figure 1D ).
MMP8 Deficiency Reduces SPCs in Atherosclerotic Lesions
To begin to investigate whether MMP8 played a role in SPC recruitment into atherosclerotic lesions, we compared the numbers of SPCs in aortic root atherosclerotic lesions from ApoE-deficient mice with or without MMP8 knockout (ApoE −/− /MMP8 −/− and ApoE −/− /MMP8 +/+ , respectively). We used a panel of well-documented stem cell markers, including CD34, Sca-1, c-kit, and Flk-1, to characterize the SPCs in atherosclerotic lesions. We found that MMP8 knockout significantly reduced the numbers of CD34 + cells (Figure 2A ), Sca-1 + cells ( Figure 2B ), c-kit + cells (Online Figure IIA) , and Flk-1 + cells (Online Figure IIB) in atherosclerotic lesions.
MMP8 Plays a Role in SPC Migration and Recruitment Into Atherosclerotic Lesions
Having found that SPCs in culture and atherosclerotic lesions expressed MMP8 and that MMP8 knockout significantly reduced SPC numbers in atherosclerotic lesions, we examined whether MMP8 had an effect on SPC migration and their recruitment into atherosclerotic lesions.
To determine whether MMP8 had an effect on SPC recruitment from the arterial lumen into atherosclerotic lesions, we performed ex vivo experiments in which we injected fluorescence-labeled embryonic Sca-1 + SPCs that had been infected with MMP8 shRNA to knockdown MMP8 or nontarget shRNA to serve as controls into the lumen of explants of mouse aortas with atherosclerotic lesions; after closing both ends of the vessels by ligation, we cultured the explants in the presence of stromal cell-derived factor-1α for 24 hours, followed by examination of fluorescencelabeled cells in the explants. We detected large numbers of fluorescence-labeled cells in the atherosclerotic lesions (and the arterial media) in the explants injected with nontarget shRNA-infected SPCs and found that the numbers of such cells were significantly smaller in the atherosclerotic lesions (and the arterial media) in the explants injected with MMP8 shRNA-infected SPCs ( Figure 3A ).
To assess whether MMP8 had an effect on SPC migration from the adventitia into the arterial media and atherosclerotic lesions, fluorescence-labeled embryonic Sca-1 + SPCs that had been infected with MMP8 shRNA or nontarget shRNA were embedded in Matrigel and then patched around the adventitia of explants of atherosclerotic aortas connected to a microcirculation system with circulating progenitor cell culture medium supplemented with stromal cell-derived factor-1α. After culturing the explants for 24 hours, we examined fluorescence-labeled cells in atherosclerotic lesions. Similar to the above experiments, we detected larger numbers Aortas with atherosclerotic lesions from ApoE −/− /MMP8 +/+ mice were cut into several segments of 5 to 10 mm in length. Embryonic Sca-1 + SPCs (10 5 cells) infected with nontarget shRNA or MMP8 shRNA were labeled with PKH26, washed, and injected into the lumen of the aortas. After ligation of the ends, the aortic segments were cultured in progenitor cell culture medium supplemented with 100 ng/mL of stromal cell-derived factor-1α for 24 hours under normal cell culture conditions (5% CO 2 , 21% O 2 , pH 7.0-7.5, 37°C). After 24 hours of incubation, the aortic segments were harvested, cross-sectioned, and microscopically examined. Green arrows indicate SPC migration direction. White arrows and arrowheads indicate migrated SPCs in the lesion area and media layer, respectively. White dotted line indicates the boundary between the lesion and healthy area. B, MMP8 knockdown reduces Sca-1 + SPC transadventitia migration. Aortas (≈10 mm in length) with atherosclerotic lesions from ApoE −/− /MMP8 +/+ mice were connected to minineedles of a microcirculation system filled with progenitor cell culture medium supplemented with 100 ng/mL of stromal cell-derived factor-1α. Embryonic Sca-1 + SPCs (10 5 cells) infected with nontarget shRNA or MMP8 shRNA were labeled with PKH26, washed, and mixed with 200 μL of Matrigel and then patched around the adventitia of the aortic segments. After 24 hours of incubation, the aortic segments were harvested, cross-sectioned, and microscopically examined. Green arrows indicate direction of SPC migration. White arrows highlight SPCs that have migrated into the lesions. White dotted line indicates the boundary between the lesion and healthy areas. Left, Representative images of aortic sections. Right, Quantitative data of Sca-1 + SPCs that have migrated into atherosclerotic lesions. Columns represent mean±SD (n=3 aortas, 10 sections per aortic segment, in each group).
of fluorescence-labeled cells in the atherosclerotic lesions (and the arterial media) in the explants patched with nontarget shRNA-infected cells than in the atherosclerotic lesions (and the arterial media) in the explants patched with MMP8 shRNA-infected cells ( Figure 3B ).
To further verify and characterize the effect of MMP8 on SPC migration, we performed in vitro migration assays using embryonic Sca-1 + SPCs that had been incubated with or without exogenous MMP8, embryonic Sca-1 + SPCs infected with MMP8 shRNA or nontarget shRNA, and bone marrow-derived SPCs from mice with or without MMP8 knockout. The assays showed that incubation with exogenous MMP8 enhanced, in a dose-dependent manner, the ability of embryonic Sca-1 + SPCs to migrate through thick Matrigel, which mimics the vascular matrix ( Figure 4A ) and their ability to transmigrate across an endothelial monolayer, which mimics vascular endothelium ( Figure 4B ). In contrast, depletion of endogenous MMP8 by shRNAs in embryonic Sca-1 + SPCs significantly reduced their migratory ability ( Figure 4C ). Consistently, Sca-1 + SPCs isolated from the bone marrow of MMP8 knockout mice had significantly lower migratory ability through matrix proteins than Sca-1 + SPCs isolated from the bone marrow of MMP8 wild-type mice ( Figure 4D and 4E).
Because it was plausible that the effect of MMP8 on cell migration would likely be partly attributable its proteolytic activity to degrade proteins in the extracellular matrix, we further investigated which types of protein in the extracellular matrix were likely to primarily account for the effect of MMP8 on cell migration. We performed migration assays using transwells coated with collagen I, collagen IV, laminin, fibronectin, or elastin, and found that MMP8 had a significant effect on embryonic Sca-1 + SPC migration through collagen I but not the other protein types tested (Online Figure III) .
Because adhesion of SPCs to the extracellular matrix could have an effect on their mobilization and migration, we further examined whether MMP8 affected SPC adhesion to Matrigel. We found that incubation of embryonic Sca-1 + SPCs with MMP8 dose-dependently inhibited their adhesion to Matrigel (Online Figure IVA) .
We also examined whether MMP8 had an effect on SPC proliferation because this potentially could be another reason for the reduction in SPC numbers in atherosclerotic lesions of MMP8 knockout mice, but we detected no such effect (Online Figure IVB) . Furthermore, we examined whether the numbers of hematopoietic SPCs (CD34 + /CD45 + cells) in the bone marrow and peripheral blood were lower in MMP8 knockout mice than in MMP8 wildtype mice because this potentially could be another reason for reduced SPC numbers in atherosclerotic lesions of MMP8-deficient mice, but we observed no such difference (Online Figure V) .
MMP8 Deficiency Reduces ADAM10 Maturation
In an ongoing study of vascular SMCs using proteomics techniques, we found a decrease of ADAM10 fragments in culture supernatants of vascular SMCs with MMP8 deficiency (unpublished data). Because ADAM10 had been shown to play a role in cell migration, 31 we examined whether MMP8 deficiency had an influence on ADAM10 on SPCs. Western blot analyses showed that the ratio of the amount of mature ADAM10 vs the amount of pro-ADAM10 in protein extracts from MMP8 shRNA-infected embryonic Sca-1 + SPCs was significantly lower than in protein extracts from nontarget shRNA-infected embryonic Sca-1 + SPCs ( Figure 5A ). Consistently, immunofluorescent staining and flow cytometry analyses using an antibody specifically against the ADAM10 prodomain showed that the levels of pro-ADAM10 on embryonic Sca-1 + SPCs were increased when MMP8 had been knocked-down by shRNA ( Figure 5B and 5C ).
To test whether MMP8 could cleave ADAM10, we incubated a recombinant mouse ADAM10 (amino acid residues 19-673, consisting of the prodomain and the other ectodomains) with active MMP8 and performed Western blot analysis using an antibody against the prohormone convertase cleavage site (amino acid residues 157-221) of ADAM10. At the baseline, in the presence or absence of MMP8, the Western blot analysis detected a band for the uncleaved recombinant protein (60 kDa) and 3 strong bands corresponding to ≈28, ≈25, and ≈18 kDa fragments, respectively ( Figure 5D ; the ≈28, ≈25, and ≈18 kDa bands are indicated by arrowheads). After 2-hour incubation without MMP8, these 4 different bands of ADAM10 remained the same, whereas after 2-hour incubation with MMP8 the intensity of the 60-kDa band was reduced, the ≈28 and ≈25 kDa bands almost completely disappeared, and a new band of ≈20 kDa appeared, whereas the intensity of the ≈18 kDa band remained approximately the same ( Figure 5D ).
MMP8 Deficiency Reduces E-cadherin Shedding Likely by ADAM10
Our ongoing study of vascular SMCs using proteomics techniques also showed a reduction of E-cadherin fragments in culture supernatants of vascular SMCs with MMP8 deficiency (unpublished data). Because it had been reported that ADAM10 could shed E-cadherin on epithelial cells and thereby promote epithelial cell migration, 31 and because we had found a reduction in the amount of mature ADAM10 on MMP8-depleted SPCs, we examined whether MMP8 knockdown or ADAM10 inhibition could lead to a change in E-cadherin on SPCs. Western blot analyses showed that 
MMP8) depletion reduces a-disintegrin-and-metalloproteinasedomain-10 (ADAM10) maturation on stem/progenitor cells (SPCs).
A to C, MMP8 knockdown reduces the amount of mature ADAM10 on SPCs. Cultured embryonic Sca-1 + SPCs were infected with nontarget shRNA or MMP8 shRNA and subjected to Western blot analysis with antibodies against ADAM10 (cytoplasmic domain), MMP8, or α-tubulin (A); immunofluorescence staining with antibodies against ADAM10 (prodomain) or MMP8 (B); and flow cytometric analysis with an antibody against ADAM10 (prodomain) (C). Representative images of Western blot, immunofluorescence staining, and flow cytometric analysis, respectively, are presented. Column chart in (A) shows quantitative data of the ratio of the amount of mature ADAM10 (M) vs the amount of pro-ADAM10 (P). Column chart in (C) shows mean fluorescence intensity for ADAM10 (prodomain) in Sca-1 + SPCs infected with nontarget shRNA or MMP8 shRNA (n=3 independent experiments). D, MMP8 cleaves ADAM10. Recombinant ADAM10 (amino acid residues 19-673, consisting of the prodomain and the other ectodomains, 500 ng; Sigma, A9975) was incubated with activated MMP8 (50 ng) in assay buffer for 0 and 2 hours, respectively, followed by Western blot analysis with an antibody against the prohormone convertase cleavage site (amino acid residues 157-221) of ADAM10 (Abcam, ab39153). Arrowheads indicate ADAM10 fragments affected by MMP8 incubation. knockdown of MMP8 in embryonic Sca-1 + SPCs with MMP8 shRNA and incubation of Sca-1 + SPCs with the ADAM10specific inhibitor GI254023X 27, 28 increased the ratio of the amount of full-length E-cadherin vs the amount of E-cadherin transmembrane cytoplasmic fragment in protein extracts from these cells ( Figure 6A1 and 6B ), suggesting a reduction in E-cadherin ectodomain shedding, probably by ADAM10, on MMP8-depleted SPCs. Consistently, flow cytometry analyses 
(MMP8) depletion or a-disintegrin-and-metalloproteinase-domain-10 (ADAM10) inhibition reduces E-cadherin shedding on stem/progenitor cells (SPCs) and decreases soluble E-cadherin-induced SPC migration.
A to C, MMP8 knockdown or ADAM10 inhibition reduces E-cadherin shedding on SPCs. Cultured embryonic Sca-1 + SPCs were infected with nontarget shRNA or MMP8 shRNA, followed by 3 days of culture in the presence or absence of the ADAM10 inhibitor GI254023X (5 µmol/L). Cell lysates were harvested and subjected to Western blot analyses with antibodies against E-cadherin (cytoplasmic domain) or MMP8 (A1). Conditioned media were also harvested and subjected to Western blot analysis with an antibody against E-cadherin (N-terminal) (A2). with an antibody specifically against E-cadherin ectodomain showed an increase in the amount of E-cadherin ectodomain on embryonic Sca-1 + SPCs when infected with MMP8 shRNA or incubated with the ADAM10 inhibitor GI254023X ( Figure  6C ), whereas Western blot analysis showed a reduction in the amount of soluble E-cadherin in the culture supernatants ( Figure 6A2) .
Previous studies indicated that soluble E-cadherin could disrupt cell-cell adhesion and induce epithelial and cancer cell migration/invasion into collagen I gel. 32, 33 Because we had observed that MMP8 knockdown led to a reduction in soluble E-cadherin generation from Sca-1 + SPCs, we investigated whether this could have an effect on SPC migration. We found that the decrease in migratory ability of embryonic Sca-1 + SPCs infected with MMP8 shRNA was significantly reduced in the presence of supernatant from cultures of embryonic Sca-1 + SPCs infected with nontarget shRNA ( Figure 6D ). Furthermore, we found that this rescuing effect of supernatant from cultures of Sca-1 + SPCs infected with nontarget shRNA was abolished if an antibody against soluble E-cadherin had been added to the supernatant to immunoprecipitate soluble E-cadherin ( Figure 6D ), suggesting that E-cadherin shedding, probably mediated by ADAM10, contributes to the effect of MMP8 on SPC migration.
To investigate whether MMP8 deficiency could have an effect on the level of soluble E-cadherin in vivo, we measured the plasma levels of soluble E-cadherin in mice with or without MMP8 knockout fed a Western diet for 12 weeks. We found that the plasma level of soluble E-cadherin was significantly lower in MMP8 knockout mice (226±261 vs 1850±2753 ng/ mL; P<0.01; n=5 per each group).
MMP8 Deficiency Reduces SPC Recruitment and Accumulation in Atherosclerotic Lesions In Vivo
Having found that MMP8 played an important role in SPC migration and recruitment in ex vivo and in vitro experiments, we further examined the in vivo effects of MMP8 on SPC migration and recruitment into atherosclerotic lesions and on lesion formation and progression. To this end, we injected ApoE −/− /MMP8 −/− mice with SPCs isolated from the bone marrow of either green fluorescence protein (GFP) transgenic or ApoE −/− /MMP8 −/− or ApoE −/− /MMP8 +/+ mice and fed the recipient mice a Western diet. In these experiments, MMP8-deficienct mice were chosen as recipients to exclude the effects of other cellular source of MMP8 on SPC migration and recruitment into atherosclerotic lesions. MagCellect Mouse Hematopoietic Cell Lineage Depletion Kit (MAGM209, R&D System), rather than single stem cell marker-positive selection, was used to isolate bone marrow SPCs for injection, because SPCs in atherosclerotic lesions are known to be heterogeneous and because no single stem cell marker can capture the entire SPC population. The suitability of using this method was confirmed by the finding that ≈90% of cells isolated using this kit were c-kit and CD34 single-or double-positive (Online Figure VI) , and ≈27% of the c-kit/CD34 double-negative cells also were positive for another stem cell marker, Sca-1 (Online Figure VI) .
In ApoE −/− /MMP8 −/− mice injected with SPCs isolated from the bone marrow of GFP transgenic mice and fed a Western diet for 12 weeks, we verified that injected SPCs (containing GFP as a marker) were recruited into and accumulated in atherosclerotic lesions (Online Figure VIIB) , and we found that they were present also in the bone marrow, peripheral blood, thymus, spleen, liver, and lung (Online Figure VIA) but undetectable in the brain, kidneys, and skeletal muscles (data not shown). We found that the majority of GFP-positive cells in atherosclerotic lesions expressed the hematopoietic cell marker CD45 (35%) or the macrophage marker CD68 (29%; Online Figure VIIB) , and some expressed the earlier SMC marker smooth muscle actin (5%; Online Figure VIIB) or the endothelial cell marker CD31 (<1%, data not shown), but none of them expressed smooth muscle myosin heavy chain, a marker for mature SMCs (Online Figure VIIB) , indicating that the injected SPCs recruited into atherosclerotic lesions differentiate mainly into leukocytes/macrophages.
In ApoE −/− /MMP8 −/− mice injected with SPCs isolated from the bone marrow of either ApoE −/− /MMP8 −/− or ApoE −/− /MMP8 +/+ mice and fed a Western diet for 6 or 12 weeks, we found that compared with the atherosclerotic lesions in those mice injected with SPCs isolated from ApoE −/− /MMP8 +/+ mice, the atherosclerotic lesions in those mice injected with MMP8-deficient SPCs (ie, isolated from ApoE −/− /MMP8 −/− mice) contained significantly fewer cells that were positive for Sca-1 ( Figure 7A ), c-kit (Online Figure VIIIA) , CD45 (Online Figure VIIIB) , or CD68 (Online Figure VIIIC) , and had a trend toward fewer smooth muscle actin-positive cells (Online Supplement Figure VIIID) , supporting that MMP8 plays an important role in SPC recruitment into and accumulation in atherosclerotic lesions in vivo. Furthermore, we found that at 12 weeks postinjection, the atherosclerotic lesions in the aortic roots of the mice injected with MMP8-deficient SPCs were significantly smaller than the atherosclerotic lesions in those mice injected with SPCs from ApoE −/− /MMP8 +/+ mice ( Figure  7B ), further supporting an important role of MMP8 in SPCs in atherosclerotic lesion formation.
Discussion
Monocytes/macrophages and SMCs represent 2 major cell types in atherosclerotic lesions and play central roles in lesion formation and progression. 1 There is substantial evidence indicating that a proportion of SMCs in atherosclerotic lesions are derived from smooth muscle progenitor cells originally residing in the arterial adventitia. [2] [3] [4] [5] There is also emerging evidence suggesting that a proportion of macrophages in atherosclerotic lesions are derived from hematopoietic SPCs, which might originate from the bone marrow and are recruited via the blood circulation into atherosclerotic lesions. [6] [7] [8] [9] [10] In agreement, our study shows the presence of SPCs in atherosclerotic lesions in ApoEdeficient mice fed a Western diet can induce atherosclerosis. Because SPCs are heterogeneous and no single marker can be used to capture the various types, 34, 35 we used a panel of welldocumented markers (CD34, Sca-1, c-kit, and Flk-1) to detect SPCs in atherosclerotic lesions in this study.
More importantly, results of our study indicate that MMP8 plays an important role in SPC migration and their recruitment into atherosclerotic lesions. We first found that compared with atherosclerotic lesions in ApoE −/− /MMP8 +/+ mice, those in ApoE −/− /MMP8 −/− mice contained fewer SPCs (CD34, Sca-1, c-kit, and Flk-1-positive cells). To specifically test the importance of MMP8 in SPCs for the SPC recruitment into atherosclerotic lesions and for lesion formation, we injected ApoE −/− /MMP8 −/− mice with SPCs from bone marrows of GFP transgenic or ApoE −/− /MMP8 −/− or ApoE −/− /MMP8 +/+ mice and fed the injected mice a Western diet. The experiment with SPCs isolated from GFP transgenic cells showed that at 12 weeks postinjection, bone marrows of the recipient mice contained GFP-positive SPCs, suggesting that the injected SPCs had been incorporated into the bone marrow. It also showed that atherosclerotic lesions in the recipient mice contained GFP-positive SPCs, most of which expressed markers of hematopoietic cells and macrophages, indicating that SPCs had been recruited into atherosclerotic lesions and differentiated into leukocytes/macrophages. The experiment with injection of SPCs from ApoE −/− /MMP8 −/− or ApoE −/− /MMP8 +/+ mice showed that atherosclerotic lesions in recipient mice injected with SPCs from ApoE −/− /MMP8 −/− mice contained fewer SPCs and were smaller than atherosclerotic lesions in mice injected with SPCs from ApoE −/− /MMP8 +/+ mice, corroborating that MMP8 from SPCs is important for SPC recruitment to atherosclerotic lesions and for lesion development. Further to these findings, our ex vivo experiments on aorta explants demonstrated that the presence of MMP8 enhanced SPC migration from the arterial lumen and the adventitia into atherosclerotic lesions, whereas in vitro experiments showed that the presence of MMP8 increased the ability of SPCs to migrate across the endothelium or through extracellular matrix. Together, these in vivo, ex vivo, and in vitro findings indicate that MMP8 in SPCs plays an important role in SPC migration, which facilitates their recruitment into atherosclerotic lesions and increases lesion development.
Cell migration involves dissociation of the migrating cells from the extracellular matrix and degradation of extracellular matrix proteins in the migratory path. Our study shows that the presence of MMP8 inhibits SPC adhesion to extracellular matrix and enhances SPC migration through extracellular matrix proteins, particularly collagen I, the principal substrate of MMP8 19 and the major constituent of the interstitial matrix of the arterial wall. 36 This provides a likely mechanistic explanation for the role of MMP8 in SPC migration and their recruitment into atherosclerotic lesions.
SPC migration also entails disruption of their interactions with each other and with stromal cells, allowing them to be released from stem cell niches in, for example, the arterial adventitia. [2] [3] [4] [5] The cell adhesion molecule E-cadherin, which is highly expressed in SPCs as shown in previous studies 37, 38 and in our present study, mediates cell-cell adhesion by the formation of homodimers of the ectodomain of E-cadherin on adjacent cells. 31, 39 Soluble E-cadherin generated by E-cadherin ectodomain shedding from the cell surface, however, can disrupt cell-cell adhesion and induce cell migration. 32, 33 Results of our study indicate that MMP8 can promote SPC migration by indirectly (probably via ADAM10) or directly increasing E-cadherin ectodomain shedding and soluble E-cadherin generation, providing another likely mechanistic explanation for the role of MMP8 in SPC migration and their recruitment into atherosclerotic lesions. A previous study shows that ADAM10 can shed E-cadherin on epithelial cells, thereby reducing E-cadherin-mediated cell-cell adhesion and promoting epithelial cell migration. 31 In this study, we found that MMP8 depletion reduced the amount of mature ADAM10 on SPCs and that knockdown of MMP8 and the presence of the ADAM10-specific inhibitor GI254023X 27,28 resulted in reduced E-cadherin shedding on SPCs. In addition, we found that soluble E-cadherin levels in the plasma were decreased in MMP8 knockout mice. Furthermore, results of in vitro experiments indicate that soluble E-cadherin in SPC culture supernatant increased migration of SPCs with MMP8 knockdown. Therefore, it seems that future work to generate MMP8/ADAM10 and MMP8/E-cadherin double-knockout mice and to further characterize these effects would be warranted. Some ADAMs, including ADAM10, when activated, possess proteolytic activity. 40, 41 Their activation often involves the removal of their prodomain. 40, 41 Although prodomain removal often occurs intracellularly, there is evidence indicating that the cell surface also contains pro-ADAMs (containing the prodomain) whose maturation (prodomain removal) can potentially take place extracellularly. [41] [42] [43] [44] The results of the Western blot, immunocytochemical, and flow cytometry analyses of our study suggest the presence of pro-ADAM10 on Sca-1 + SPC surface and that the presence of MMP8 reduces the amount of pro-ADAM10 and increases the amount of mature ADAM10 on these cells. Our in vitro assays showed that incubation of a recombinant mouse ADAM10 (amino acid residues 19-673, consisting of the prodomain and the other ectodomains) with active MMP8 resulted in the generation of cleaved ADAM10 products detectable by an antibody against the ADAM10 prohormone convertase cleavage site (amino acid residues 157-221) in Western blot analysis. Although the exact cleavage sites are unknown and further studies are warranted, our data suggest that MMP8 can cleave ADAM10, which could potentially explain the finding of our study that the presence of MMP8 reduces pro-ADAM10 and increases mature ADAM10 on Sca-1 + SPCs.
Our recent study showed that MMP8 deficiency reduces atherosclerotic lesion formation in ApoE knockout mice fed a Western diet, with reduced lesional macrophage and SMC content, 26 indicating a causal role of MMP8 in the pathogenesis of atherosclerosis. This previous study also revealed evidence indicating that the role of MMP8 in atherogenesis is partly attributable to an MMP8-mediated increase in angiotensin II generation, leading to increased blood pressure and increased expression of vascular cell adhesion molecule-1 that plays an important role in leukocyte recruitment. 1 However, given the complexity of atherogenesis, and because MMP8 can potentially cleave multiple types of proteins with different functions, it is plausible that multiple mechanisms contribute to the role of MMP8 in atherogenesis. The finding of this study that MMP8 enhances SPC recruitment into atherosclerotic lesions indicates that this likely represents another mechanism for the role of MMP8 in atherogenesis. It is possible that reduced SPC recruitment into atherosclerotic lesions in MMP8-deficient mice is partly because of the reduced inflammatory surrounding and, therefore, attenuated chemotaxis of SPCs into the vascular wall. However, results of the in vivo experiments comparing MMP8-deficient mice injected with either MMP8-deficient SPCs or MMP8 wild-type SPCs indicate that MMP8 expression by SPCs themselves also plays an important role in their recruitment into atherosclerotic lesions.
In summary, our study shows that MMP8 plays a functional role in SPC migration and their recruitment into atherosclerotic lesions, and that MMP8 expression by SPCs contributes to atherosclerotic lesion formation in ApoEdeficient mice. The data from this study provide new insight into the biological molecules and related mechanisms involved in the regulation of SPC migration and in the pathogenesis of atherosclerosis.
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